The use of a vaccine-based approach to prostate cancer suffered yet another blow Jan. 11 when Germany’s CureVac AG reported disappointing results for its RNActive prostate cancer vaccine CV9104 in a Phase IIb clinical trial. However, there may be good reasons not to be too downcast; there are more than half-a-dozen other potential therapeutic vaccines in late-stage clinical studies, according to Informa Pharma Intelligence’s database, Biomedtracker.
Not only that, the world’s first therapeutic prostate cancer vaccine, Dendreon Corp.’s Provenge (sipuleucel-T), which was first approved for marketing in the US in 2010 but has been a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
